POLE and neoplasm: Broader panels with the ability to analyze hundreds of genes can indeed identify a greater number of druggable molecular alterations, define the tumor mutational burden, and detect increasingly informative mutations such as POLE/D1 mutations which are predictive of sensitivity to immunotherapies.